| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SR8278 | CTRPv2 | pan-cancer | AAC | -0.29 | 0.03 |
| mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | -0.2 | 0.2 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | -0.19 | 7e-06 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | -0.18 | 0.1 |
| mRNA | OSI-906 | CTRPv2 | pan-cancer | AAC | -0.15 | 0.0002 |
| mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.01 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.01 |
| mRNA | BRD-K99584050 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.02 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0003 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0005 |